nach oben

Erschienen in:

01.12.2011 | Review

Antigens in chronic myeloid leukemia: implications for vaccine development

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

Treatment with imatinib mesylate and other tyrosine kinase inhibitors (TKI) revolutionized the therapy of chronic myeloid leukemia (CML). However, it alone does not cure this disease. Moreover, some patients develop resistance or adverse effects to this therapy. As successful treatment of a portion of CML patients by hematopoietic stem cell transplantation (HSCT) suggests the importance of immune mechanisms in the elimination of leukemic cells, including leukemia stem cells, TKI administration or HSCT might be combined with vaccination to cure CML patients. However, antigens implicated in the immune responses have not yet been sufficiently identified. Therefore, in this report, we compiled and characterized a list of 165 antigens associated with CML (CML-Ag165) and analyzed the expression of the corresponding genes in CML phases, subpopulations of leukemic cells, and CML-derived cell lines using available datasets from microarray transcriptional-profiling studies. From the CML-Ag165 list, we selected antigens most suitable for vaccine development and evaluated their appropriate characteristics.

Nur mit Berechtigung zugänglich

Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619–1630PubMedCrossRef

Savona M, Talpaz M (2008) Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 8:341–350PubMedCrossRef

Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76–94PubMedCrossRef

Jamieson CH, Ailles LE, Dylla SJ et al (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351:657–667PubMedCrossRef

Gangemi R, Paleari L, Orengo AM, Cesario A, Chessa L, Ferrini S, Russo P (2009) Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem 16:1688–1703PubMedCrossRef

Pinilla-Ibarz J, Shah B, Dubovsky JA (2009) The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control 16:141–152PubMed

Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grunebach F, Brossart P (2007) BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 67:5489–5497PubMedCrossRef

Scheich F, Duyster J, Peschel C, Bernhard H (2007) The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens. Blood 110:2556–2560PubMedCrossRef

Rezvani K (2011) Peptide vaccine therapy for leukemia. Int J Hematol 93:274–280PubMedCrossRef

10.

Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4:3CrossRef

11.

Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57CrossRef

12.

Saeed AI, Sharov V, White J et al (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34:374–378PubMed

13.

Papadopoulos KP, Suciu-Foca N, Hesdorffer CS, Tugulea S, Maffei A, Harris PE (1997) Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood 90:4938–4946PubMed

14.

Knights AJ, Weinzierl AO, Flad T, Guinn BA, Mueller L, Mufti GJ, Stevanovic S, Pawelec G (2006) A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias. Leukemia 20:1067–1072PubMedCrossRef

15.

Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014–2021PubMedCrossRef

16.

Greiner J, Schmitt M (2008) Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol 80:461–468PubMedCrossRef

17.

Vonka V (2010) Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2:227–241PubMedCrossRef

18.

Jaras M, Johnels P, Hansen N et al (2010) Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 107:16280–16285PubMedCrossRef

19.

Yong AS, Stephens N, Weber G et al (2011) Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia 25:629–637PubMedCrossRef

20.

Grunebach F, Mirakaj V, Mirakaj V, Muller MR, Brummendorf T, Brossart P (2006) BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res 66:5892–5900PubMedCrossRef

21.

Drexler HG, MacLeod RA, Uphoff CC (1999) Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk Res 23:207–215PubMedCrossRef

22.

Smith BD, Kasamon YL, Kowalski J et al (2010) K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 16:338–347PubMedCrossRef

23.

Andersson A, Eden P, Lindgren D et al (2005) Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia 19:1042–1050PubMedCrossRef

24.

Schmidt S, Gastl G, Wolf D (2008) Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia. Leuk Lymphoma 49:643–647PubMedCrossRef

25.

Yong AS, Melo JV (2009) The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol 22:181–190PubMedCrossRef

26.

Diaz-Blanco E, Bruns I, Neumann F et al (2007) Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21:494–504PubMedCrossRef

27.

Crossman LC, Mori M, Hsieh YC et al (2005) In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 90:459–464PubMed

28.

Yong AS, Szydlo RM, Goldman JM, Apperley JF, Melo JV (2006) Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107:205–212PubMedCrossRef

29.

Radich JP, Dai H, Mao M et al (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103:2794–2799PubMedCrossRef

30.

Lemoli RM, Salvestrini V, Bianchi E et al (2009) Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34− cell population with intrinsic resistance to imatinib. Blood 114:5191–5200PubMedCrossRef

31.

McWeeney SK, Pemberton LC, Loriaux MM et al (2010) A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 115:315–325PubMedCrossRef

32.

Burguillo FJ, Martin J, Barrera I, Bardsley WG (2010) Meta-analysis of microarray data: the case of imatinib resistance in chronic myelogenous leukemia. Comput Biol Chem 34:184–192PubMedCrossRef

33.

Liu R, Mitchell DA (2010) Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. Cancer Immunol Immunother 59:183–193PubMedCrossRef

34.

Sturrock AB, Franklin KF, Rao G, Marshall BC, Rebentisch MB, Lemons RS, Hoidal JR (1992) Structure, chromosomal assignment, and expression of the gene for proteinase-3. The Wegener’s granulomatosis autoantigen. J Biol Chem 267:21193–21199PubMed

35.

Dengler R, Munstermann U, al-Batran S, Hausner I, Faderl S, Nerl C, Emmerich B (1995) Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 89:250–257PubMedCrossRef

36.

Hosen N, Sonoda Y, Oji Y et al (2002) Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms’ tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 116:409–420PubMedCrossRef

37.

Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ (2008) Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22:1721–1727PubMedCrossRef

38.

Maxwell CA, McCarthy J, Turley E (2008) Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 121:925–932PubMedCrossRef

39.

Greiner J, Ringhoffer M, Taniguchi M et al (2002) Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 30:1029–1035PubMedCrossRef

40.

Giannopoulos K, Dmoszynska A, Kowal M et al (2010) Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia 24:798–805PubMedCrossRef

41.

Watari K, Tojo A, Nagamura-Inoue T, Nagamura F, Takeshita A, Fukushima T, Motoji T, Tani K, Asano S (2000) Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett 466:367–371PubMedCrossRef

42.

Oehler VG, Guthrie KA, Cummings CL et al (2009) The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 114:3299–3308PubMedCrossRef

43.

Kanojia D, Garg M, Saini S, Agarwal S, Kumar R, Suri A (2010) Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia. Leuk Res 34:858–863PubMedCrossRef

44.

Hofmann S, Greiner J (2010) Immunogenic antigens as therapeutic targets against myeloid leukaemic cells. Leuk Res 34:850–851PubMedCrossRef

45.

Karthigeyan D, Prasad SB, Shandilya J, Agrawal S, Kundu TK (2011) Biology of aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev 31:757–793

46.

Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, Kuzushima K, Yasukawa M (2009) Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 113:66–74PubMedCrossRef

47.

Cammareri P, Scopelliti A, Todaro M et al (2010) Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 70:4655–4665PubMedCrossRef

48.

Lessard J, Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423:255–260PubMedCrossRef

49.

Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV (2007) The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110:380–383PubMedCrossRef

50.

Rizo A, Horton SJ, Olthof S et al (2010) BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood 116:4621–4630PubMedCrossRef

51.

Ross DM, Hughes TP, Melo JV (2011) Do we have to kill the last CML cell? Leukemia 25:193–200PubMedCrossRef

52.

Wu CJ (2008) Immunologic targeting of the cancer stem cell. In: The Stem Cell Research Community (ed) StemBook. doi:10.3824/stembook.1.21.1, http://www.stembook.org

53.

Chen CI, Maecker HT, Lee PP (2008) Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 111:5342–5349PubMedCrossRef

54.

Chen YT, Scanlan MJ, Sahin U et al (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914–1918PubMedCrossRef

55.

Gnjatic S, Nishikawa H, Jungbluth AA, Gure AO, Ritter G, Jager E, Knuth A, Chen YT, Old LJ (2006) NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95:1–30PubMedCrossRef

56.

Lin YW, Beharry ZM, Hill EG et al (2010) A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115:824–833PubMedCrossRef

57.

Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX (2009) PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119:362–375PubMed

58.

Eichmann A, Yuan L, Breant C, Alitalo K, Koskinen PJ (2000) Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene 19:1215–1224PubMedCrossRef

59.

Fontana S, Alessandro R, Barranca M, Giordano M, Corrado C, Zanella-Cleon I, Becchi M, Kohn EC, De Leo G (2007) Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J Proteome Res 6:4330–4342PubMedCrossRef

60.

Steidl U, Kronenwett R, Rohr UP et al (2002) Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood 99:2037–2044PubMedCrossRef

61.

Ng YY, van Kessel B, Lokhorst HM, Baert MR, van den Burg CM, Bloem AC, Staal FJ (2004) Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity. J Leukoc Biol 75:314–323PubMedCrossRef

62.

Zheng C, Li L, Haak M et al (2006) Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20:1028–1034PubMedCrossRef

63.

Yong AS, Rezvani K, Savani BN, Eniafe R, Mielke S, Goldman JM, Barrett AJ (2007) High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood 110:770–775PubMedCrossRef

64.

Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R, Seifarth W (2005) Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia 19:1192–1197PubMedCrossRef

65.

Patel H, Gordon MY (2009) Abnormal centrosome-centriole cycle in chronic myeloid leukaemia? Br J Haematol 146:408–417PubMedCrossRef

66.

Gerber JM, Qin L, Kowalski J et al (2011) Characterization of chronic myeloid leukemia stem cells. Am J Hematol 86:31–37PubMedCrossRef

67.

Mumprecht S, Matter M, Pavelic V, Ochsenbein AF (2006) Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108:3406–3413PubMedCrossRef

68.

Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM (2007) The kinase inhibitor imatinib—an immunosuppressive drug? Curr Cancer Drug Targets 7:251–258PubMedCrossRef

69.

Kim PS, Lee PP, Levy D (2008) Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol 4:e1000095PubMedCrossRef

70.

Barrett J, Rezvani K (2009) Immunotherapy: can we include vaccines with stem-cell transplantation? Nat Rev Clin Oncol 6:503–505PubMedCrossRef

71.

Plimack ER, Kantarjian HM, Issa JP (2007) Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma 48:1472–1481PubMedCrossRef

72.

Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M (1999) Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J Immunother 22:16–24PubMedCrossRef

73.

Adair SJ, Hogan KT (2009) Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother 58:589–601PubMedCrossRef

74.

Goodyear O, Agathanggelou A, Novitzky-Basso I et al (2010) Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116:1908–1918PubMedCrossRef

75.

Fioretti D, Iurescia S, Fazio VM, Rinaldi M (2010) DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010:174378PubMedCrossRef

76.

Chaise C, Buchan SL, Rice J et al (2008) DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 112:2956–2964PubMedCrossRef

77.

Ling M, Wen YJ, Lim SH (1998) Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia. Blood 92:4764–4770PubMed

78.

Wu CJ, Yang XF, McLaughlin S et al (2000) Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 106:705–714PubMedCrossRef

79.

Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Dohner H, Schmitt M (2003) Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 106:224–231PubMedCrossRef

80.

Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S, Wells JW, Banham AH, Mufti GJ (2005) Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 335:1293–1304PubMedCrossRef

81.

Takahashi H, Furukawa T, Yano T et al (2007) Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients. Exp Hematol 35:1091–1099PubMedCrossRef

82.

Biernacki MA, Marina O, Zhang W et al (2010) Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res 70:906–915PubMedCrossRef

83.

Zou L, Wu Y, Pei L et al (2005) Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. Leuk Res 29:1387–1391PubMedCrossRef

84.

Adams SP, Sahota SS, Mijovic A, Czepulkowski B, Padua RA, Mufti GJ, Guinn BA (2002) Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 16:2238–2242PubMedCrossRef

85.

Schmitt M, Li L, Giannopoulos K et al (2006) Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol 34:1709–1719PubMedCrossRef

86.

Luetkens T, Schafhausen P, Uhlich F et al (2010) Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res 34:1647–1655PubMedCrossRef

87.

Lim SH, Austin S, Owen-Jones E, Robinson L (1999) Expression of testicular genes in haematological malignancies. Br J Cancer 81:1162–1164PubMedCrossRef

88.

Martinez A, Olarte I, Mergold MA et al (2007) mRNA expression of MAGE-A3 gene in leukemia cells. Leuk Res 31:33–37PubMedCrossRef

89.

Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G (2007) PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature. Leuk Res 31:365–369PubMedCrossRef

90.

Zhang Y, Wang Z, Liu H, Giles FJ, Lim SH (2003) Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies. J Immunother 26:461–467PubMedCrossRef

91.

Wang Z, Zhang Y, Mandal A, Zhang J, Giles FJ, Herr JC, Lim SH (2004) The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin Cancer Res 10:6544–6550PubMedCrossRef

92.

Wang Z, Zhang Y, Liu H, Salati E, Chiriva-Internati M, Lim SH (2003) Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood 101:955–960PubMedCrossRef

93.

Sanchez-Garcia I, Grutz G (1995) Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 92:5287–5291PubMedCrossRef

94.

Nosaka T, Kitamura T (2002) Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation. Exp Hematol 30:697–702PubMedCrossRef

95.

Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y, Oka Y, Tanizawa Y (2003) MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation. Oncogene 22:7774–7780PubMedCrossRef

96.

Hakansson P, Lassen C, Olofsson T, Baldetorp B, Karlsson A, Gullberg U, Fioretos T (2004) Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a). Leukemia 18:538–547PubMedCrossRef

97.

Cilloni D, Messa F, Gottardi E et al (2004) Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 101:979–988PubMedCrossRef

98.

Hakansson P, Nilsson B, Andersson A, Lassen C, Gullberg U, Fioretos T (2008) Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. Genes Chromosom Cancer 47:267–275PubMedCrossRef

99.

Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, Neumann F (2009) Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia 23:983–985PubMedCrossRef

100.

Bhattacharyya J, Mihara K, Yasunaga S, Tanaka H, Hoshi M, Takihara Y, Kimura A (2009) BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia. Ann Hematol 88:333–340PubMedCrossRef

101.

Graham SM, Vass JK, Holyoake TL, Graham GJ (2007) Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 25:3111–3120PubMedCrossRef

102.

Bruns I, Czibere A, Fischer JC et al (2009) The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 23:892–899PubMedCrossRef

103.

Hughes TR, Mao M, Jones AR et al (2001) Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol 19:342–347

104.

Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, Dohner H, Schmitt M (2004) mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 108:704–711PubMedCrossRef

105.

Elisseeva OA, Oka Y, Tsuboi A et al (2002) Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99:3272–3279PubMedCrossRef

106.

Yamagami T, Sugiyama H, Inoue K et al (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87:2878–2884PubMed

107.

Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018–1023PubMedCrossRef

108.

Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE (1989) Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell 59:959–968PubMedCrossRef

109.

Roman-Gomez J, Jimenez-Velasco A, Agirre X et al (2007) Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res 31:1521–1528PubMedCrossRef

110.

Rezvani K, Yong AS, Tawab A et al (2009) Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 113:2245–2255PubMedCrossRef

111.

Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122:835–847PubMedCrossRef

Titel: Antigens in chronic myeloid leukemia: implications for vaccine development
Publikationsdatum: 01.12.2011
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 12/2011
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1126-z

Springer Medizin

Antigens in chronic myeloid leukemia: implications for vaccine development

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2011

Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity

Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function

H2O2 production within tumor microenvironment inversely correlated with infiltration of CD56dim NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction

Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?

Prognostic impact of B-cell density in cutaneous melanoma

Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie